Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGIR | P43119 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17891729 | 0.81 | KDM4C (0.49) | KDM4CNR3C1 | |
| SCHEMBL7777522 | 0.79 | SIGMAR1 (0.57) | KDM4C | |
| SCHEMBL15839876 | 0.78 | KDM4C (0.46) | KDM4C | |
| SCHEMBL17891701 | 0.77 | KDM4C (0.46) | KDM4CL3MBTL1 | |
| SCHEMBL19383337 | 0.77 | KDM4C (0.46) | KDM4CL3MBTL1 | |
| SCHEMBL17061174 | 0.75 | PTGDR2 (0.47) | KDM4CFFAR1PPARD | |
| SCHEMBL3020498 | 0.75 | ESR1 (0.59) | FFAR1PPARD | |
| SCHEMBL3590904 | 0.75 | FFAR1 (0.52) | KDM4CFFAR1TP53L3MBTL1PPARD | |
| SCHEMBL30301824 | 0.75 | FFAR1 (0.52) | KDM4CFFAR1TP53L3MBTL1PPARD | |
| SCHEMBL22905344 | 0.75 | KDM4C (0.52) | KDM4CNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2128154-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | ORMDL3, OXA1L, OGFRL1 | KDM4C 3938/4885FFAR1 70/4885TBXA2R 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.